ACA SPELLS BIG CHANGE IN METHODS WOMEN WILL USE FOR BIRTH CONTROL
January 30, 2013
Phoenix Marketing International to Introduce ACA Market Impact Kit to Help Brands Understand Changes
Durham, NC – Free birth control may result in quantum shift in the most popular methods and spell big change of some major brands. Data from Phoenix Marketing International’s December 360°Contraceptive Market survey among 1000 women, aged 18-45, point to a flood of women talking to their doctor in the first quarter of 2013 with intentions to switch to a different method of contraceptives. Long acting methods – that were once more expensive alternatives – are prime candidates to steal share from their formerly less expensive short-acting oral contraceptive options.
Nearly half of the women aware of free birth control option (45%), plan to take action in the first quarter 2013. And nearly half of those are thinking of switching to long acting methods like IUDs offered by Bayer, including Mirena, as well as the newly approved Skyla, or to the category non-hormonal option of ParaGard. However, other key brands offering longer protection include Pfizer’s Depo-Provera, Merck’s Nuvaring, and their newer transdermal option Nexplanon, are going to benefit from the shift from once a day oral contraception to longer acting brands.
The Affordable Care Act (ACA) is changing everything in terms of how brands will need to build their marketing strategy to maintain or grow in 2013. To stay in touch, with monthly changes on your brand, ask about Phoenix Marketing International’s “ACA Market Impact Kit” today; contact Doug Zabor at 919-767-0500 or Doug.Zabor@PhoenixMI.com.
The Phoenix Healthcare birth control audit is part of a growing family of disease category consumer studies that offer Phoenix exclusive 360° Marketview©. Phoenix Healthcare 360° Marketview studies currently cover 40% of all DTC spending in the US with research in the following categories: Contraceptives, Crohn’s Disease, Diabetes, Men’s Health, Osteoporosis, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis, and a partial list of the major brands tracked in these programs include: Actemra, AndroGel, Cialis, Cimzia, Enbrel, Essure, Humira, Januvia, Levitra, Mirena, Orencia, Ortho TriCyclen-Lo, ParaGard, Plan B, Rapiflo, Remicade, Rituxan, Simponi, Stelara, Uloric, Viagra, and Victoza.Back to Explore